Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial
- 5 January 2021
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 73 (5) , 721-724
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Trends in Utilization of Urate‐Lowering Therapies Following the US Food and Drug Administration’s Boxed Warning on FebuxostatArthritis & Rheumatology, 2021
- Colchicine in Patients with Chronic Coronary DiseaseNew England Journal of Medicine, 2020
- Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trialThe Lancet, 2020
- Efficacy and Safety of Low-Dose Colchicine after Myocardial InfarctionNew England Journal of Medicine, 2019
- Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort studyRheumatology, 2019
- Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population‐Based Cohort Study and Meta‐AnalysisClinical Pharmacology & Therapeutics, 2019
- Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus AllopurinolCirculation, 2018
- New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety AlertArthritis & Rheumatology, 2018
- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with GoutNew England Journal of Medicine, 2018
- Editorial: The Ethics of Recent Gout TrialsArthritis & Rheumatology, 2016